384 results about "Use medication" patented technology

The invention discloses a drug-combined anticancer composition and application of the composition in preparation of anticancer drugs. According to the present invention, the drug combination composition comprises the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate, the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate provide the synergistic effect, and compared with the single PARP inhibitor, the drug combination composition has characteristics of high stomach cancer sensitivity, significant gastric cancer efficiency improving, and wide application prospect. The Amlodipine in the drug combination composition provided by the invention enhances the curative effect of the PARP inhibitor Olaparib on the gastric cancer.

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.

The invention provides an inhalation medication auxiliary device, relates to the technical field of medical instruments, and solves the technical problem that a large force is needed when a puncture part of an inhaler is pressed to puncture a capsule. The inhalation medication auxiliary device comprises a shell and an automatic puncturing module, and the shell covers an inhaler and is used for fixing the inhaler; the automatic puncturing module is arranged on the shell and used for automatically puncturing the capsule placed in the inhaler. According to the embodiment of the invention, the automatic puncturing of the capsule in the inhaler is realized through the automatic puncturing module arranged on the shell, so that the technical problems that large force is needed when the puncturing part of the inhaler is pressed to puncture the capsule, a user with weak force is difficult to press, and the inhaler is not friendly to old and young users are solved.

The invention discloses a production and preparation method of palatability-enhanced compound double-flower oral liquid, and relates to the technical field of traditional Chinese medicine preparations. The production and preparation method of the oral liquid comprises the following steps: pretreatment of medicinal materials: taking herba andrographitis, honeysuckle, radix isatidis, fructus forsythiae, honey and dark plum, washing, denucleating and slicing the dark plum (the honey is in a liquid state and does not need to be pretreated), ultrasonic extraction, integrated purification, filtrate collection, dynamic taste modification, sterilization and filling; the method has the advantages that bitter components are accurately neutralized by an innovative gradient inclusion process, qualitative leap of a bitter masking effect is realized, sensory evaluation is verified according to international standards, children acceptance score reaches an excellent level (full score of 10 scores), the core problem that children refer to take medicines due to bitter taste is thoroughly solved, the treatment compliance of patients is remarkably improved, and the treatment cost is reduced. The continuity of medication is ensured, a breakthrough solution is provided for the field of medication for children, and meanwhile, a technical normal form is provided for improvement of medicines similar to bitter taste.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

The utility model relates to the technical field of airflow detection, in particular to an inspiration airflow detection device, which comprises an airflow channel which is a longitudinal ventilation cavity enclosed by a shell. The airflow guide cavity is formed in the top of the airflow channel, a first ventilation opening is formed in the bottom end of the shell, and a second ventilation opening is formed in the side wall of the airflow guide cavity; the second air vent is used for being communicated with an air inlet of the dry powder medicine preparation, and the shape of the second air vent is matched with that of the air inlet of the dry powder medicine preparation connected with the second air vent; and the sensor mechanism is arranged on the side wall of the shell. The inspiration airflow detection device provided by the utility model can be matched with a dry powder medicine preparation for use, is used for detecting the flow rate of the inspiration airflow of a patient in the medication process, and solves the problem that a gas flow sensor is difficult to be matched with the dry powder medicine preparation in the prior art.

The invention discloses application of licochalcone as a drug sensitizer and an anti-tumor drug composition. The application comprises an application of the acanthochalcone in preparation of an anti-tumor drug sensitizer and an application of the acanthochalcone in improvement of the anti-tumor efficacy of platinum chemotherapeutic drugs, and the invention further provides an anti-tumor composition capable of efficiently inhibiting platinum drug-resistant gastric cancer cells based on the application. Through a gastric cancer organ model and an in-vitro cytology experiment, it is found that the acanthochalcone has an inhibiting effect on proliferation of gastric cancer cells, and the sensitivity of the gastric cancer cells to platinum drugs can be remarkably enhanced. The invention also finds that IC50 of gastric cancer cells to cis-platinum and oxaliplatin, especially platinum acquired drug-resistant gastric cancer cells, can be significantly reduced by combined use of the acanthochalcone and platinum drugs. Therefore, the invention provides a new medication basis and choice for overcoming acquired platinum drug resistance of gastric cancer by utilizing the acanthochalcone.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a novel dosage form of an isavuconazole sulfate freeze-dried tablet, and a prescription and a process for preparing the isavuconazole sulfate freeze-dried tablet by adopting a freeze-drying method. The isavuconazole sulfate freeze-dried tablet is prepared from isavuconazole sulfate serving as a main drug and pharmaceutic adjuvants. Water is not needed during taking, and the tablet can be rapidly disintegrated after being put in the mouth and is suitable for patients with dysphagia such as old people and children; the production process of the isavuconazole sulfate freeze-dried orally disintegrating tablet is simple in technology, easy to control and suitable for industrial production.

The invention discloses application of tangeretin in preparation of a medicine for treating hearing loss. The invention proposes and verifies that the tangeretin can effectively protect the spiral ganglion neurons for the first time, and avoids the death of the cells caused by cisplatin medication; experimental data show that the preventive tangeretin drug can effectively prevent hearing loss of adult mice and greatly relieve sensorineural deafness caused by cis-platinum, and a new thought is provided for clinical ototoxicity drug administration.

The invention discloses a traditional Chinese medicine compound composition with an effect of preventing and treating radioactive injury as well as a preparation method and application thereof. The traditional Chinese medicine compound composition is prepared from 5-15 parts of American ginseng, 3-6 parts of sea-buckthorn and 10-30 parts of rhizoma polygonati. The composition is proportioned and optimized according to the theory of treatment based on syndrome differentiation, and the medicines are combined to achieve the effects of tonifying qi, activating blood and nourishing yin. Clinical experiment results show that the traditional Chinese medicine compound composition provided by the invention has a remarkable effect of preventing and treating radioactive injury, particularly has a remarkable curative effect in the aspects of improving oral mucositis, dry mouth, weakness, sleep disorder and the like after radiotherapy, and is safe in clinical medication.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

This application relates to a rifapentine-containing pharmaceutical composition and its preparation method. The rifapentine-containing granules are prepared by dry granulation, which reduces the content of impurities present in existing pharmaceutical compositions, especially the content of the genotoxic impurity 1-cyclopentan-4-nitrosopiperazine, thereby improving the safety and efficacy of the drug.

The invention relates to the technical field of medicines, in particular to a briracetam oral solution and a preparation method thereof. According to the present invention, by adjusting the formula and the preparation process of the oral solution of the briracetam, the stability of the briracetam is effectively improved, the antibacterial effect is effectively improved without adding the preservative, the taste of the oral solution is adjusted, and the medication compatibility of children patients is improved.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from aspirin, atorvastatin, valsartan, hydrochlorothiazide, folic acid substances and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition provided by the invention has the advantages that the pharmaceutical composition provided by the invention has a multi-target synergistic prevention effect on vascular diseases, especially cerebral embolism, that is, the composition not only can reduce blood pressure, blood fat and blood homocysteine level, but also has an effect of preventing thrombosis, and reduces the risk of cerebral apoplexy. In addition, the form of the pharmaceutical composition is beneficial to improving the medication compliance of patients.

The invention provides a method for treating AR negative TNBC through combination of quercetin and enzalutamide, the quercetin up-regulates the AR expression level by inhibiting a high-expression solute carrier SLC7A5, so that tumor cells which are not sensitive to enzalutamide originally obtain drug sensitivity again; the combined use of an AR antagonist enzalutamide (1-80 [mu] M) can cooperatively block an AR signal channel and significantly inhibit cell proliferation (the inhibition rate of drug combination is 70%, Plt, 0.01 higher than that of a single drug). In-vitro experiments prove that the scheme has a synergistic effect (the effect is optimal when the mass ratio is 1: 1-5: 1) in MDA-MB-231 cells, and an animal model shows that the tumor volume inhibition rate reaches 70% or above. Safety evaluation shows that the drug combination does not cause abnormity of serum biochemical indexes (ALT / AST / BUN / CREA) or damage of main organs and tissues. The invention further provides a preparation method of an oral preparation (tablets / capsules / nanoparticles) containing quercetin (50-500 mg / day) and enzalutamide (40-160 mg / day), and a new strategy is provided for reversing AR-TNBC drug resistance.

The invention provides a method for separating and determining impurities in thiopride hydrochloride, liquid chromatography is adopted for separating and determining, a chromatographic column adopted by the liquid chromatography is a C18 column, a mobile phase comprises a mobile phase A and a mobile phase B, the mobile phase A is 0.02-0.15 Vt% ammonia water, the mobile phase B is methanol, and the detection wavelength is 240 nm. According to the method provided by the invention, the impurities in the thiopride hydrochloride can be effectively separated from the thiopride hydrochloride, and the impurities can also be remarkably distinguished, so that a theoretical basis is provided for quality evaluation of the thiopride hydrochloride, and safe medication of a patient is ensured.

Disclosed are an anthracycline compound, a preparation method therefor, an intermediate, and a use thereof. The present invention provides an anthracycline compound as shown in formula I or a pharmaceutically acceptable salt thereof. The anthracycline compound provided by the present invention has antitumor activity comparable to existing anthracycline drugs (such as nemorubicin) or greater than that of existing anthracycline drugs doxorubicin and daunorubicin, and does not form an oxazole ring structure during metabolism, thereby improving the clinical safety of such drugs.

The invention relates to a qualitative and quantitative method for detecting active ingredients of root-strengthening and cough-relieving granules through UPLC-MS / MS, and belongs to the technical field of medicine analysis and detection. The four active ingredients of liquiritigenin, isoliquiritigenin, luteolin and bakuchiol in a sample can be detected at the same time. The method comprises the following steps: pretreating a sample by a 70% methanol ultrasonic extraction method to obtain a target sample solution, and detecting by using an SCIEX ExionLC AE high-pressure liquid phase system and an AB SCIEX 4500 mass spectrometer in combination with an MRM mode. Carrying out gradient elution on a liquid phase by using an HSS T3 C18 chromatographic column and 0.1% formic acid water-acetonitrile as a mobile phase; the mass spectrum is electrospray negative ion scanning, and a specific ion source and MRM parameters are set. The method can rapidly separate the four components, is short in detection period, high in sensitivity and strong in matrix interference resistance, can be accurately qualitative and quantitative, and provides support for preparation quality evaluation, pharmacodynamic mechanism research and clinical reasonable medication.

The application belongs to the technical field of pharmaceutical preparations, and discloses a trimetazidine hydrochloride tablet and a preparation process thereof.The trimetazidine hydrochloride tablet is composed of trimetazidine hydrochloride, lactose, microcrystalline cellulose, sodium crosslinked carboxymethyl cellulose and other auxiliary materials, and specific auxiliary components are added simultaneously.The preparation process comprises the following steps in sequence: pretreatment of core components, inclusion and dispersion, mixing of soft materials, granulation, drying, total mixing and tablet pressing, and the solubility and dispersibility of the drug are effectively improved.The trimetazidine hydrochloride tablet can realize rapid and sufficient release of the drug, has excellent content uniformity, provides precise and stable dose guarantee for clinical medication, and meets the clinical treatment requirements.

To provide a clothing-integrated medicine case that enables a user to always carry medicine on his / her person so as to reduce forgetting to take medicine or searching for a place to put it and to reduce the time and effort required to transfer medicine to another bag when going out. [Solution] This device is designed to allow commonly used medications to be carried around by placing them in an inner pouch i inside multiple square-shaped pockets b attached to clothing a. When taking medication, the user looks at the letters written in each square, removes the inner pouch from the pocket, and takes the medication. Since the letters e and f written on the pocket are close to the eyes when it is time to take the medication, the user is less likely to forget to take the medication.

The invention relates to perillaseed oil nanoemulsion eye drops as well as a preparation method and application thereof, and belongs to the technical field of medicines. The perillaseed oil nanoemulsion eye drops comprise the following raw material components in parts by mass: 1-20 parts of perillaseed oil, 0.1-10 parts of an emulsifier, 0-10 parts of a co-emulsifier, 0.05-3 parts of a metal ion chelating agent and 1-5 parts of an osmotic pressure regulator. By adding the metal ion chelating agent and controlling the preheating temperature, the problem that perillaseed oil is easy to oxidize is solved. According to the perilla oil nanoemulsion eye drops, the perilla oil serves as an effective component to exert the drug effect and also serves as an oil phase, meanwhile, the particle size of the nanoemulsion is accurately controlled by adjusting the variety of the co-emulsifier, and the safety and stability of the perilla oil nanoemulsion eye drops are further improved. The perillaseed oil eye drops provided by the invention can effectively relieve the symptoms of xerophthalmia and asthenopia, and a new medication choice is provided for treating xerophthalmia and myopia.

The application belongs to the field of traditional Chinese medicines, and particularly relates to a new use of a Mailuoshutong preparation, namely, a use of the Mailuoshutong preparation in preparation of a medicine for treating anal fistula. The Mailuoshutong preparation is mainly prepared from Huangqi, Jinyinhua, Huangbai, Cangzhu, Yiyiren, Xuanshen, Danggui, Baishao, Gancao, Shuiji, Wugong and Quanxie. The clinical use result shows that the Mailuoshutong preparation (granules / pills) has a high effective rate in treating anal fistula, can obviously improve the clinical symptoms of the patients with anal fistula, and reduce the pain of the patients, thereby providing a new drug selection for the patients with anal fistula.

The invention discloses a dexketoprofen trometamol nasal spray and a preparation method thereof, a buffering agent is used as a stabilizer, and the dexketoprofen trometamol nasal spray which is good in stability, small in irritation, convenient, rapid in effect taking and extremely small in side effect is provided, so that the medication compliance of patients and the convenience of clinical medication are improved; after being administrated, the nasal spray can be quickly absorbed through nasal mucosa, the absorption speed is equivalent to that of intramuscular injection, the nasal spray can quickly reach the peak concentration as intramuscular injection, and the curative effect can be quickly exerted; the preparation has the advantages of no first-pass effect during nasal mucosa administration, high bioavailability and rapid absorption, is suitable for self-rapid analgesia, and is stable in process and suitable for large-scale production.

The application discloses a composition containing a peripheral vasodilator and a 5alpha-reductase inhibitor, effectively solves the transdermal inhibition of the peripheral vasodilator on the 5alpha-reductase inhibitor by adding a specific penetration enhancer, improves the transdermal rate of the active ingredients in the pharmaceutical composition by proportion adjustment, greatly improves the synergistic effect of local combined medication, avoids the side effects brought by oral 5alpha-reductase inhibitor, and improves the safety of the medicine.

The invention discloses a medical biological dressing suppository matrix and a preparation method thereof, and relates to the technical field of suppositories, the medical biological dressing suppository matrix is prepared by taking gelatin, glycerol, polyethylene glycol derivatives and chitosan quaternary ammonium salt as raw materials, the biocompatibility of the suppository matrix is good, and stimulation and anaphylactic reaction cannot be generated on a medication cavity; and after the suppository matrix is dissolved in the cavity, a film with good adhesion can be formed on the mucous membrane of the cavity, so that the released medicine is fully contacted with the focus for a long time, the curative effect and bioavailability of the medicine are improved, and the suppository is suitable for preparing suppositories for treating gynecological diseases, anorectal diseases and prostate diseases.

The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

The invention provides a memantine derivative or a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of the memantine derivative, and application of the memantine derivative in preparation of drugs for preventing and / or treating central nervous diseases, especially Alzheimer's disease, Parkinson's disease or other neurodegenerative diseases. The compound disclosed by the invention is small in water solubility, can be well prepared into a suspension preparation, has a relatively low dissolution speed in a living body, can achieve the effect of lasting the drug effect for several weeks after single administration, reduces the medication frequency of a patient, improves the compliance of the patient, also ensures the curative effect, and has a relatively good application prospect.

The invention provides a marker for predicting caries occurrence based on saliva metabolites, which is characterized by comprising 4-acetaminobutyric acid, adipic acid, pantetheine and palmitoyl ethanolamide, and the marker is used for preparing a kit for detecting the caries occurrence risk of a subject. The invention provides four markers in saliva metabolites, and early warning of future caries can be realized in a non-invasive and low-cost manner; according to the basis of detection numerical values of the markers, the morbidity state of the constant dentition caries can be reflected, so that accurate prevention and control of the caries can be realized, and finally the purposes of reducing the morbidity of the caries, helping disease pathological typing and researching drug action targets, accurate medication and pathogenesis can be achieved.

The invention relates to a composition for preventing or treating oral inflammation or oral ulcer, and belongs to the technical field of oral care medicines. The technical scheme of the invention is as follows: the composition contains one or more of lactose-N-trisaccharide and fucosyllactose, and / or lactose-N-tetrasaccharide (Lacto-N-tetraose, LNT) and / or lactose-N-neotetrasaccharide (Lacto-N-neotetraose, LNnT), and the preparation method of the composition comprises the following steps of: mixing the lactose-N-trisaccharide, the fucosyllactose and the lactose-N-tetraose and the lactose-N-neotetraose. According to the technical scheme, the problems that (1) sticking occurs in the tabletting process, and tablets with smooth surfaces cannot be prepared are solved, and (2) the stability problem of buccal tablets in the storage process is stabilized, and the stable and effective composition for treating or preventing inflammation is provided.